Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Financial Collapse of 2001 Unwinding -- Ignore unavailable to you. Want to Upgrade?

To: elmatador who wrote (12924)	8/19/2024 8:14:22 AM
From: E_K_S	Read Replies (1) \| Respond to of 13783

So if Harris looks to a Federal ban on price gouging specific to food, what about other sectors? Rents, fuel or even chips (like NVDA AI chips)? What would stop Federal price limits on the current & next generation NVDA chips? That's what I will be watching . .

To: elmatador who wrote (12924)	8/20/2024 1:34:16 AM
From: Snowshoe	Read Replies (1) \| Respond to of 13783

No problema, amigo! Just carpet-bomb the planet with Ozempic and food prices will crash... -ggg- Ozempic Is Making People Buy Less Food, Walmart Says bloomberg.com By Brendan Case and Shelly Banjo October 4, 2023 Walmart Inc. says it’s already seeing an impact on food-shopping demand from people taking the diabetes drug Ozempic, Wegovy and other appetite-suppressing medications. “We definitely do see a slight change compared to the total population, we do see a slight pullback in overall basket,” John Furner, the chief executive officer of Walmart’s sprawling US operation, said in an interview Wednesday. “Just less units, slightly less calories.” The Bentonville, Arkansas-based retailer is studying changes in sales patterns using anonymized data on shopper populations. It can look at the purchasing changes among people taking the drug and can also compare those habits to similar people who aren’t taking the shots. Furner said it’s too early to draw any definitive conclusions about the appetite-suppressing drugs made by Novo Nordisk A/S, and similar medicines. An increasing number of CEOs and investors are talking about how popular weight-loss drugs might change the economy and business. Earlier this week, the CEO of the maker of Pringles and Cheez-Its said the company is studying their potential impact on dietary behaviors. “Like everything that potentially impacts our business, we’ll look at it, study it and, if necessary, mitigate,” Steve Cahillane, the CEO of Kellanova, said in an interview.